ABSTRACT-Sepsis remains a challenge for intensive care physicians, as it keeps up with high mortality rate in spite of the high costs associated with its treatment. Several studies indicate that the infusion of Drotrecogin-alpha activated (DrotAA) reduce mortality in patients at high risk of death when administered early and secured the appropriate initial treatment of sepsis as recommended by Surviving Sepsis Campaign. Europe and United States of America differ regarding the criteria of high risk of death in sepsis, two or more organ dysfunctions and Acute Physiology and Chronic Health Evaluation 25 or more, respectively. In addition to varied definitions of high risk of death for inclusion of patients in sepsis studies, the possibility of bleeding related to drug use and intrinsic limitations related to study design led the Company to develop a new randomized, multinational, placebo-controlled, double-blind study to assess the effectiveness of drug in patients with septic shock in adults.
INTRODUCTION
Sepsis remains a major challenge for health care givers and managers because it imposes high annual costs in different countries, and the mortality rate is still elevated (1, 2) . In this context, several therapeutic interventions have been trialed to reduce sepsis-related lethality (3Y5). Among these interventions, activated protein C (APC) has been launched in the market as a unique efficacious compound approved to treat patients with severe sepsis (6) .
However, its efficacy is still a matter of debate. Since the pivotal study PROWESS, several randomized and nonrandomized clinical trials have been performed and published, and the results could be interpreted as not confirmatory of efficacy. There are some reasons for questioning APC efficacy. First, the PROWESS Study was stopped early, and the respective results could be interpreted with caution. Second, APC has been suggested to be used in patients at a high risk of death. However, this recommendation was based in a subgroup analysis, which is prone to overestimation, and the identification of those high-risk patients is not straightforward. Hence, the right patient suitable for this therapy has not been easily identified. Finally, there is a strong concern regarding its safety because this compound has been associated with a higher risk of severe bleeding.
More recently, after the European Medicines Agency (EMEA) request, the Company has decided to organize a new randomized clinical trial to assess the efficacy of APC only in adult patients with severe septic shock and a high risk of death. After this trial, we will be able to confirm the efficacy of this compound or if it should be abandoned.
This review article sought to organize the current knowledge about APC by showing the rational for its use and the main randomized controlled trial results. In addition, we share some perspectives about the PROWESS-Shock Trial.
RATIONALE FOR ACTIVATED PROTEIN C USE IN SEPSIS
Sepsis patients have important alterations in inflammatory and coagulation pathways. Many cytokines, chemokines, and activated inflammatory cells are increased in sepsis. Coagulation abnormalities range from subtle activation of coagulation, undetectable by common coagulation tests, small decreases in platelet count, and subclinical prolongation of global clotting times to disseminated intravascular coagulation (DIC). Sepsis patients with severe DIC may present thrombosis and/or bleeding from various sites, leading to multiple organ dysfunctions (7) .
Activation of the inflammatory system can result in activation of coagulation, and the opposite may also occur; coagulation proteases can affect inflammatory pathways (8) . The APC seems to play a central role in pathogenesis of these disturbances in sepsis because there are evidences showing that protein C pathway is impaired in sepsis, contributing to the derangement of coagulation disturbance (9, 10) . Protein C zymogens' form is activated by endothelial cell bound to thrombomodulin, which is activated by thrombin (11) . The APC acts together with protein S cofactor and can, through proteolysis, degrade the coagulation cofactors Va and VIIa. Then, APC exerts an important anticoagulation effect. Receptors to protein C at the endothelium (endothelial protein-C receptor [EPCR] ) accelerate that activation and serve as APC receptors, amplifying the anticoagulation and anti-inflammatory effects of APC (12) . Plasma levels of zymogen protein C are low or very low because of impaired synthesis, consumption, and degradation by proteolytic enzymes such as neutrophil elastase (13Y15). The APC is also diminished by downregulation of thrombomodulin after the release of proinflammatory cytokines. Cofactor protein S is also deficient because acutephase inflammatory disease leads to an increase in complement regulatory protein that binds to protein S. Then, low levels of free protein S and impairment of the APC system contribute to a procoagulant state during sepsis (16, 17) .
Experimental and clinical evidence shows that the use of recombinant human APC (rhAPC) promotes benefits. Experimental models in sepsis have shown a reduction of mortality in animals that received rhAPC (18) . The rhAPC also diminished thrombotic events, affected fibrinolysis by inhibiting plasminogen activator inhibitor type 1, blocked the activity of plasminogen activator inhibitor type 1, enhanced clot lysis, and improved microcirculatory perfusion (19Y21). Monoclonal antibodies against EPCR of septic animals resulted in a more severe response to sublethal Escherichia coli bacteremia (22) . Anti-inflammatory effects were also demonstrated, probably related by the EPCR-APC complex, which can modulate gene expression, cytokine levels, leukocyte chemotaxis, and adhesion of circulating leukocytes to the activated endothelium, and protect against disruption of the endothelial cell barrier in sepsis (23, 24) .
CLINICAL TRIAL REVIEW
The PROWESS Study was a large, multicenter, doubleblind, placebo-controlled trial in which sepsis patients with one or more organ dysfunctions received Drotecogin-! activated (DrotAA) or placebo within 24 h after the first organ dysfunction (6) . More than 70% of patients had cardiovascular dysfunction and required mechanical ventilation. Patients treated with DrotAA presented a 6.1% reduction in absolute risk of death at the 28th day, from 30.8% to 24.7%, and a 20% reduction in the relative risk of death (P = 0.005). The study was interrupted early because it reached the stopping rule for efficacy, previously established. Patients treated with DrotAA also showed a faster resolution in cardiovascular and respiratory dysfunctions (25) . However, the incidence of serious bleeding was higher in the DrotAA group than in the placebo group (3.5% vs. 2.0%; P = 0.06).
Subgroup analyses performed revealed a survival benefit independent of sex, age, type of infection, type of pathogen, surgical status, and biochemical measures of disease severity, including protein C levels (26Y28). Patients with less severe disease, presenting with a single organ dysfunction or Acute Physiology and Chronic Health Evaluation II (APACHE II) score of less than 20, had no survival benefit.
After the PROWESS Study, a safety trial was needed because DrotAA has been approved by the Food and Drug Administration (FDA) for the treatment of severe sepsis. An open-label single-arm trial called the Extended Evaluation of Recombinant Human Activated Protein C (ENHANCE) begun in March 2001 (29) . Primary objectives were to provide additional safety and efficacy information concerning the use of DrotAA among patients with severe sepsis. Patients could be treated with DrotAAup to 48 h after the first sepsis-induced organ dysfunction. Although APACHE II scores were lower in ENHANCE than PROWESS, all other measures of disease severity were higher (i.e., more patients on vasopressors, mechanically ventilated, with multiple organ dysfunctions, and higher total sequential organ failure assessment [SOFA] score).
During the drug administration, 3.6% of ENHANCE patients experienced a serious bleeding event in comparison with 2.4% and 1.0% in DrotAA-and placebo-treated patients from the PROWESS Study, respectively. In addition, 15 patients (0.6%) experienced one intracranial hemorrhage event during that period, as opposed to 0.2% in PROWESS. A significant time Â reatment effect was also observed. Patients treated within the first 24 h exhibited lower mortality rate than patients treated after the first 24 h, regardless of disease severity. These data may suggest that more effective use of DrotAA could be achieved by initiating treatment earlier.
In addition, FDA required another study to evaluate the efficacy of DrotAA for adults who had severe sepsis and a low risk of death. Patients with a single sepsis-induced organ failure or an APACHE II score less than 25 were enrolled in ADDRESS (Administration of Drotrecogin alfa activated in early-stage Severe Sepsis) Study, a double-blind, placebocontrolled, randomized trial (30) . Death from any cause assessed at 28 days after beginning of drug infusion was the primary end point.
The monitoring committee recommended early termination of study because the chances of achieving the main objective was less than 5% (futility). Therefore, no differences in 28-day mortality were found in both placebo and DrotAA groups (17% vs. 18.5%, respectively). Moreover, the risk for bleeding associated with the drug was confirmed. Serious bleeding events occurred in 2.4% and 1.2% (P = 0.02) in DrotAA-and placebo-treated patients, respectively. The number of central nervous system bleeding was similar in both groups (0.3% vs. 0.2%).
After those three trials, some statements could be made. First, DrotAA should be used only in more severe conditions such as in patients with sepsis-induced multiple organ dysfunctions. Second, caution should be exercised before using this compound in patients at risk for bleeding, including those with low platelet counts. Third, the drug should be administered within 24 h after the first sepsis-induced organ dysfunction. Finally, patients at low risk of death, for instance, with single organ dysfunction, and after recent surgery, should not receive DrotAA.
Two other studies have to be mentioned because they are considered for the current recommendation for using DrotAA in sepsis patients. First, the RESOLVE Study (Researching severe Sepsis and Organ dysfunction in children: a global perspective) has evaluated the efficacy and safety of DrotAA in more than 450 patients younger than 17 years with sepsisinduced cardiovascular and respiratory failure (31) . The main end point was the time of organ failure resolution (Composite Time to Complete Organ Failure Resolution Score). The study demonstrated no significant difference between groups in Composite Time to Complete Organ Failure Resolution Score (P = 0.72) or in 28-day mortality (placebo, 17.5%; DrotAA, 17.2%; P = 0.93). Importantly, CNS bleeding was more frequent in the DrotAA group (4.6%) than in the placebo group (2.1%), although not significantly (P = 0.13), particularly in children younger than 60 days. After this trial and according to the Surviving Sepsis Campaign guidelines (32), DrotAA is not indicated for critically ill sepsis children.
Second, the XPRESS study has verified the interaction between heparin and DrotAA (33) . Considering that DrotAA is an anticoagulant drug, and an in vitro study has shown a lower activity of protein C, the concomitant use of both compounds could result in bleeding and/or reduction of efficacy of DrotAA. Hence, a randomized, double-blind, phase 4, equivalence design trial involving 1994 patients suitable for DrotAA administration was performed. Three groups were prospectively defined: patients assigned to receive lowYmolecular weight heparin, unfractionated heparin, or placebo. The main finding of this study was that there is no harmful interaction between heparin and DrotAA because the occurrence of severe bleeding was similar in the three groups. Interestingly, heparin coadministration was associated with a nonsignificant reduction in 28-day mortality in patients randomized to treatment with heparin. Finally, the association of DrotAA and heparin compared with DrotAA and placebo was not associated with a lower incidence of venous thromboembolism events. Considering these data, it would be inappropriate to forgo concomitant heparin prophylaxis in patients with severe sepsis receiving treatment with DrotAA.
After the conclusion of those trials, two observational studies were published describing the use of DrotAA in real life. The Canadian study (34) has enrolled 261 consecutive patients who received DrotAA from March 2003 to February 2004. Twentyfive percent of patients received the compound after 24 h of the first sepsis-induced organ dysfunction, and only 64% of the patients received DrotAA within 72 to 96 h. The mortality rate was 45% (higher than PROWESS and ENHANCE studies) and was associated with age older than 65 years, multiple organ failure, and nosocomial source of infection. Patients treated within 12 h had a lower mortality rate. Serious adverse bleeding events were observed in 10% of patients, including one CNS bleeding followed by death during the infusion period.
The Italian study, published in the same issue as the Canadian study, has used a pharmacosurveillance program to evaluate 668 DrotAA treatments (35) between 2003 and 2006. Similar to the Canadian study, only 64% of patients completed the course without any interruption, severe bleeding was observed in 5%, and overall mortality rate reached 46%. Off-label use was quite frequent: 13.6% before and 27.8% after the introduction of the timing restriction by the EMEA. Taking together those studies, we could conclude that the mortality and severe bleeding were higher than in controlled trials, suggesting, in real-life patients, more severe diseases and more contraindications. However, the ideal patient for this treatment still remains unclear. As stated before, patients at a high risk of death could be ideal, but the definition of high risk is a matter of debate.
HIGH RISK OF DEATH DEFINITION
Developing effective therapies for any disease process relies on the ability to clearly define the population of patients who could benefit from that intervention. In accordance with the mentioned clinical trials, DrotAA could be effective in patients at high risk of death. Up to now, APACHE II score and organ failure development have been used to characterize those patients. However, one could speculate that besides those tools, these patients should have a pathophysiological derangement where DrotAA would act. For instance, patients with DIC would have more benefit by using this drug than those without DIC (36) , suggesting that the more severe the endothelial activation, the more effective should DrotAA administration be. In line with this thought, some studies have demonstrated the association with low activity of protein C and mortality, and the use of DrotAA in these patients is more beneficial than in patients with normal or higher activity of protein C.
Even when we use organ dysfunction development as a criterion for choosing the right patient, some questions have been raised. First, organ dysfunction is a nonstatic condition and as such should be dynamically evaluated. A couple of years ago, we have demonstrated that changes in organ dysfunction (worsening or improving), during the first day of therapy, is useful to identify patients at higher risk of death (37) . Therefore, dynamic evaluation is superior to static one performed at the intensive care unit admission.
More recently, the predisposition-infection-response-organ dysfunction (PIRO) approach has been proposed to better characterize sepsis patients and segregate between severe and nonsevere populations (38) . The PIRO system offers a possible means of forming more homogeneous subgroups of patients who have sepsis, who could then receive better targeted interventions with the prospect of real therapeutic advances. For instance, some authors have already demonstrated that in patients with community-acquired pneumonia (39) and in those with ventilation-associated pneumonia (40) , the use of PIRO score was able to accurately discriminate different groups regarding mortality risk. However, further studies are needed before widely using the PIRO score to definitively characterize highrisk patients.
Finally, the presence of shock per se is a useful marker of severity (41) and easily recognized. Moreover, there is some evidence that DrotAA could prevent sepsis-induced hypotension in a human study (42) , and the relative risk reduction of death was more prominent in those patients treated with DrotAA (6).
WHY THE DRUG IS SO CONTROVERSIAL
Even after several studies, DrotAA remains controversial. Limitations of studies, difficulties to classify high risk patients and risk of bleeding are the main reasons for necessity another trial. The PROWESS study modified the protocol during patient enrollment: alteration of exclusion criteria, replacement of placebo (0.9% sodium chloride solution by 0.1% human serum albumin), and modified manufacturing of study drug.
Because of the United States and Europe's definition of high-risk patients, the ADDRESS Study included patients with APACHE 25 or more in Europe and with two or more organ dysfunctions in United States. If these patients are considered as high risk of death they should not be enrolled in the ADDRESS trial, a study for mild and moderate sepsis. Post hoc analysis in patients with an APACHE II score of more than 25 showed a 28-day mortality of 24.7% and 29.5% in the placebo and DrotAA groups, respectively. In patients with two or more organ dysfunctions, 28-day mortality rates were 21.9% and 20.7% in the placebo and DrotAA groups, respectively. However, in these two populations with severe sepsis, the basal risk of death was much lower than in the corresponding subgroups from the PROWESS trial.
As mentioned earlier, there is evidence of increased risk of bleeding in those groups receiving DrotAA. The trials showed higher benefits/risks in patients with more severe disease, but it is needed to refine the actual high-risk population that benefits from the use of DrotAA (43) .
PROTOCOL OVERVIEW (PROWESS-SHOCK STUDY [F1K-MC-EVDP PROTOCOL])
In 2007, the EMEA stated that the benefit/risk balance of DrotAA required additional clarification, and that another clinical trial should be performed to assert the benefit/risk profile of DrotAA in a specific population at high risk of death. The Eli Lilly and Company agreed to sponsor another randomized controlled trial and has invited a steering committee to design the trial. This committee has written an article to describe the protocol as well as the relationship between the committed and the sponsor (44) . In this comprehensive article, the authors describe the process by which the trial was developed, major decisions regarding trial design, and plans for independent analysis, interpretation, and reporting of the data.
The main inclusion criteria of the PROWESS-Shock Study are: (a) adult patients (older than 18 years); (b) infection requiring i.v. antimicrobial therapy; (c) at least two of the four SIRS criteria; (d) septic shock, defined as patient must have received 30 mL kg j1 of i.v. fluid administered within the period spanning the 4 h before and 4 h after initiation of vasopressor therapy; and (e) at least 1 of the following criteria: metabolic acidosis, renal dysfunction, or acute hepatic dysfunction. Besides, patients must remain vasopressor dependent throughout the pretreatment period and through the time of randomization with the goal of maintaining a mean arterial pressure of 65 mmHg or higher with reasonable attempts made to wean the vasopressor support. The DrotAA should be infused during 96 h at 242g kg j1 h j1 and compared with placebo infusion. The primary outcome is mortality in the intention-to-treat population at 28th day after randomization. Interestingly, the protocol states that if the mortality rate is less than 30% after 750 patients have been enrolled, the sample size may be increased by up to 500 subjects (the actual sample size was calculated as being 1,500 patients and will provide 80% power to detect a relative risk reduction of 20% with an ! of 0.05).
Another key point of this protocol is regarded with the rules for stopping the trial. The steering committee has established (a) not stopping the trial for futility; (b) two interim analyses are planned, and the unblended data will be reviewed only by DMC and not by the steering committee; and (c) in the first interim analysis, there will be no stopping efficacy rules. Those decisions are based on the previous discussions after controversial FDA approval. For the second interim analysis at 1,000 patients, if DAA is superior to placebo at a P G 0.001 and if at least 250 deaths have occurred, the trial must be stopped.
Another critical ethical question is related to the use of a licensed drug in a placebo-controlled trial. Only centers where the senior treating clinician has clinical equipoise or substantial uncertainty over the balance of the benefits and risks associated with treatment with DrotAA should be participating. Finally, this trial should provide definitive evidence about its use with no doubt regarding the benefit or its absence. By the end of December 2009, more than 600 patients had been randomized, and the study probably will be concluded by December 2010.
PERSPECTIVES
The Surviving Sepsis Campaign has established in the last revision that BWe suggest that adult patients with sepsisinduced organ dysfunction associated with a clinical assessment of high risk of death, most of whom will have APACHE II greater than or equal to 25 or multiple organ failure, receive rhAPC if there are no contraindications (grade 2B, except for patients within 30 days of surgery where it is grade 2C).[ Relative contraindications should also be considered in decision making. In contrast, we recommend that adult patients with severe sepsis and a low risk of death, most of whom will have APACHE II less than 20 or one organ failure, do not receive rhAPC (grade 1A). This statement summarizes the best evidence available at this time and is based on the data discussed in this review article. However, during the following months and before we receive the data from the PROWESSShock Study, what could we anticipate about the future of DrotAA use? We think that the results are largely dependent on three factors. First, the definition of shock does not consider enough time to assess severity. As we have previously discussed, the dynamic evaluation of organ dysfunction is a better predictor of mortality than the static one. In that article, patients 24 h after the first treatment with no vasopressor agent, but under high-dose vasopressors at intensive care unit admission, had the same outcome. It is uncertain that 4 h is enough to draw the same conclusion. So, those patients could be misclassified as severe. Second, although the protocol has established additional 500 patients if mortality rate is lower than 30%, we are not convinced that this strategy will mitigate the effect of a persistent low mortality rate. In other words, if the trial does not include severe patients, the mortality will be low and it could reflect the inclusion of less severe patients where the compound has no effect. Third, there are some evidences showing that DrotAA could be more effective in sepsis patients with lung involvement (45) . Some experts have advocated that DrotAA should be used in septic shock patients and acute lung injury. In addition, the efficacy of DrotAA surgery patients is controversial regardless the number of organ dysfunction. Hence, if the PROWESS-Shock Trial enrolls more surgical patients and less patients with acute lung injury, the final result could be negative.
